CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-01 | GOLDSMITH MARK A See Remarks | Option exercise 10b5-1 | +10,000 | $4.09 | $41K | 310,170 |
| 2024-10-01 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −7,978 | $44.80 | $357K | 302,192 |
| 2024-10-01 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −2,022 | $45.46 | $92K | 300,170 |
| 2024-10-01 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 271,229 | ||
| 2024-09-16 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −2,244 | $44.19 | $99K | 98,932 |
| 2024-09-16 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −11,715 | $44.19 | $518K | 300,170 |
| 2024-09-16 | Horn Margaret A Chief Operating Officer | Sale 10b5-1 | −4,331 | $44.19 | $191K | 132,320 |
| 2024-09-16 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −4,665 | $44.19 | $206K | 264,408 |
| 2024-09-16 | Cislini Jeff General Counsel | Sale 10b5-1 | −1,454 | $44.19 | $64K | 45,634 |
| 2024-09-13 | Kelsey Stephen Michael See Remarks | Option exercise 10b5-1 | +16,667 | $4.09 | $68K | 285,740 |
| 2024-09-13 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −5,966 | $42.75 | $255K | 279,774 |
| 2024-09-13 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −10,701 | $43.65 | $467K | 269,073 |
| 2024-09-13 | Kelsey Stephen Michael See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,667 | 39,998 | ||
| 2024-08-21 | Weber Barbara Director | Returned to the company | −1,808 | $44.83 | $81K | 18,265 |
| 2024-08-13 | Kelsey Stephen Michael See Remarks | Option exercise 10b5-1 | +16,667 | $4.09 | $68K | 285,740 |
| 2024-08-13 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −16,667 | $42.98 | $716K | 269,073 |
| 2024-08-13 | Kelsey Stephen Michael See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,667 | 56,665 | ||
| 2024-08-05 | Clyburn Frank Director | Grant or award · Stock Option (Right to Buy) | +26,540 | 26,540 | ||
| 2024-08-05 | Clyburn Frank Director | Grant or award | +6,932 | 6,932 | ||
| 2024-08-05 | Clyburn Frank Director | Grant or award · Stock Option (Right to Buy) | +27,744 | 27,744 |
Page 22 of 29 · 569 trades